Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19

The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precede...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rory J. Malek, Colin A. Bill, Charlotte M. Vines
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Anti-viral Protease inhibitor Anti-inflammatory Monoclonals Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/364d9da931374ad2a294199f3f0fa877
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:364d9da931374ad2a294199f3f0fa877
record_format	dspace
spelling	oai:doaj.org-article:364d9da931374ad2a294199f3f0fa8772021-11-14T04:29:09ZClinical drug therapies and biologicals currently used or in clinical trial to treat COVID-190753-332210.1016/j.biopha.2021.112276https://doaj.org/article/364d9da931374ad2a294199f3f0fa8772021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S075333222101060Xhttps://doaj.org/toc/0753-3322The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in treating COVID-19, remdesivir, although other therapies are authorized for emergency use due to this pandemic being a public health emergency. In this review, twenty-four different treatments are discussed regarding their use against COVID-19 and any potential future coronavirus-associated illnesses. Their traditional use, mechanism of action against COVID-19, and efficacy in clinical trials are assessed. Six treatments evaluated are shown to significantly decrease mortality in clinical trials, and ten treatments have shown some form of clinical efficacy.Rory J. MalekColin A. BillCharlotte M. VinesElsevierarticleAnti-viralProtease inhibitorAnti-inflammatoryMonoclonalsTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112276- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anti-viral Protease inhibitor Anti-inflammatory Monoclonals Therapeutics. Pharmacology RM1-950
spellingShingle	Anti-viral Protease inhibitor Anti-inflammatory Monoclonals Therapeutics. Pharmacology RM1-950 Rory J. Malek Colin A. Bill Charlotte M. Vines Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
description	The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in treating COVID-19, remdesivir, although other therapies are authorized for emergency use due to this pandemic being a public health emergency. In this review, twenty-four different treatments are discussed regarding their use against COVID-19 and any potential future coronavirus-associated illnesses. Their traditional use, mechanism of action against COVID-19, and efficacy in clinical trials are assessed. Six treatments evaluated are shown to significantly decrease mortality in clinical trials, and ten treatments have shown some form of clinical efficacy.
format	article
author	Rory J. Malek Colin A. Bill Charlotte M. Vines
author_facet	Rory J. Malek Colin A. Bill Charlotte M. Vines
author_sort	Rory J. Malek
title	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
title_short	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
title_full	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
title_fullStr	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
title_full_unstemmed	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
title_sort	clinical drug therapies and biologicals currently used or in clinical trial to treat covid-19
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/364d9da931374ad2a294199f3f0fa877
work_keys_str_mv	AT roryjmalek clinicaldrugtherapiesandbiologicalscurrentlyusedorinclinicaltrialtotreatcovid19 AT colinabill clinicaldrugtherapiesandbiologicalscurrentlyusedorinclinicaltrialtotreatcovid19 AT charlottemvines clinicaldrugtherapiesandbiologicalscurrentlyusedorinclinicaltrialtotreatcovid19
_version_	1718430007158636544

Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19

Ejemplares similares